Page 278 of 347: studies 2,771 to 2,780 of 3,461, newest first. Back to the MDMA overview
August 30, 2024 Franklin King Iv
Psychedelics have been used therapeutically for thousands of years by various cultures, and the term "novel therapeutic agent" should not describe them. The classic psychedelics are mainly tryptamines (e.g., psilocybin, DMT, LSD) and phenethylamines (e.g., MDMA, mescaline, 2C-B), with tryptamines being more studied currently. While most psychedelics are medically safe, some like ibogaine and...
August 30, 2024
SSRIs may not block the subjective or therapeutic effects of psychedelics, but more research is needed. MDMA is completely blocked by SSRIs and SNRIs, while ibogaine has strong QT prolonging effects and should not be combined with other QT prolonging drugs. Ayahuasca contains an MAOI and may cause serotonin syndrome if combined with antidepressants. Lithium and psychedelics may increase seizure...
August 30, 2024
Psychedelics generally elicit a profound change in consciousness, often with ego dissolution, mystical experiences, and enriched sensory perception, but are medically safe for most. Tachyphylaxis occurs after repeated psychedelic administration, preventing biological dependence. MDMA may have some abuse potential and less tachyphylaxis compared to LSD/psilocybin. Psychedelics have 5-HT2B...
Clinical Case Reports August 30, 2024 Seragnoli Federico, Martignoni Geo, Martignoni Entela et al. 3 citations
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a patient with throat cancer experiencing significant existential distress. The patient tolerated the intervention well. This case supports the feasibility and safety of PAT for patients with life‐threatening conditions in a home setting. Abstract...
Clinical chemistry and laboratory medicine August 27, 2024 Théo Willeman, Justine Grunwald, Marc Manceau et al. 3 citations
Smartphones have become everyday objects on which the accumulation of fingerprints is significant. In addition, a large proportion of the population regularly uses a smartphone, especially younger people. The objective of this study was to evaluate smartphones as a new matrix for toxico-epidemiology. This study was conducted during two separate events (techno and trance) at an electronic music...
Mental Health Weekly August 19, 2024 Valerie A. Canady
In a closely watched decision involving the use of psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)‐assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA‐assisted therapy to its drug maker, Lykos Therapeutics.
Alcoholism & Drug Abuse Weekly August 16, 2024 Alison Knopf
The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post‐traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for‐profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to...
Journal of Chromatography A August 16, 2024 Nayna Cândida Gomes, Oscar G Cabrices, Bruno Spinosa de Martinis 12 citations
Widespread consumption of drugs of abuse worldwide has caused concern: it adversely affects public health, individual safety, and social structures. Experts are particularly alarmed because new psychoactive substances have been increasingly detected in biological samples. In recent years, several studies have focused on developing methods to identify psychoactive substances in alternative...
EClinicalMedicine August 1, 2024 Marcus Hughes, Albert Garcia‐romeu 42 citations
Prior data indicate limited ethnoracial diversity in studies testing psychedelic-assisted treatments. Regulatory approval for psychedelic treatments may be imminent given growing evidence for safety and efficacy in a variety of psychiatric conditions. Data on racial and ethnic inclusion rates in clinical psychedelic studies since 2018 have not been systematically reported to date. With the...
International Journal of Drug Policy August 1, 2024 Stephanie Lake, Philippe Lucas 31 citations
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations across international jurisdictions remains limited. We implemented the Global Psychedelic Survey (GPS) to capture information about psychedelic consumer characteristics, access, and usage patterns around the world. The GPS was administered online in...